Quote:

---

I’ve begun to receive many inquiries recently about our most advanced therapeutic program, Eltoprazine, following the announcement of our first interaction with the FDA.

The company intends to be active in business development for this asset.
See more at: www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/eltoprazine-lympro-manf-path-forward-value-creation/#sthash.vOsFUrK1.dpuf

@SG- Will be part of the updates to come shortly, including FDA update on Elto. On track with our stated plans
7:01am - 16 Oct 14

---

I find it interesting that in the last CB, GC for the first time changed the order of Assets. ELTOP was moved up into first spot. Then, LymPro.

Could the first piece of news that we hear be on ELTOP? Are things essentially set in place for LymPro and we're just now waiting for news on ELTOP & FDA?

Very interesting..of course IMHO...

Cheers